Dicaris is a brand-name medication that contains levamisole as its active ingredient. Levamisole belongs to the antiparasitic class of drugs and is supplied as a 50 mg oral pill. In Hong Kong, levamisole-containing products are subject to local pharmaceutical regulations and may be prescribed only by a qualified healthcare professional.
Levamisole exerts its antiparasitic effect by interfering with the metabolic pathways of nematodes (roundworms). The drug is taken up by the parasite, where it disrupts microtubule formation and inhibits the synthesis of essential proteins, ultimately leading to paralysis and death of the worm. In humans, levamisole is absorbed from the gastrointestinal tract, reaches peak plasma concentrations within 1-2 hours, and is partially metabolized by the liver before renal excretion.
Levamisole is approved in several jurisdictions for the treatment of intestinal helminth infections, specifically:
These indications are based on its antiparasitic activity against common soil-transmitted nematodes. In Hong Kong, clinicians may prescribe levamisole for these infections when other first-line agents are unsuitable or unavailable.
Some clinical studies have explored levamisole as an immunomodulatory agent in conditions such as:
These uses are not approved by Hong Kong’s Department of Health or comparable regulatory bodies. Off-label use requires close medical supervision, individualized risk assessment, and regular monitoring for adverse effects.
This article provides educational information about Dicaris and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Levamisole disrupts the microtubule formation within the parasite, impairing its ability to move and feed, which leads to paralysis and death of the worm.
Combining antiparasitics is generally unnecessary and may increase the risk of side effects; discuss any combination therapy with a pharmacist or physician.
Most patients notice a reduction in gastrointestinal symptoms within 24-48 hours, although complete eradication requires the full treatment course and follow-up stool testing.
Yes, levamisole is widely employed as a deworming agent for livestock and companion animals, but formulations and dosages differ from those prescribed for humans.
Levamisole can cause transient leukopenia, so a clinician may request a CBC before and after treatment to ensure blood cell counts remain within normal limits.
When traveling, keep the medication in its original packaging with a pharmacist-signed proof of prescription to satisfy customs or airline security checks.
No specific food restrictions are required; however, maintaining a balanced diet supports overall health and may help mitigate mild gastrointestinal upset.
Both are antiparasitics, but levamisole primarily targets nematodes by disrupting microtubules, whereas albendazole inhibits tubulin polymerization and has a broader spectrum against various helminths.
Patients with reduced renal function should have dosing adjusted and be monitored closely, as levamisole is partially excreted unchanged by the kidneys.
A mild rash may be a normal reaction, but if it spreads, becomes painful, or is accompanied by fever, seek medical attention promptly as it could signal an allergic response.
